CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $22.40.

A number of brokerages recently commented on CBLL. Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group upped their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. BTIG Research lifted their price objective on shares of CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th.

Insider Activity at CeriBell

In related news, Director William W. Burke sold 2,207 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.84, for a total value of $43,786.88. Following the sale, the director directly owned 23,022 shares in the company, valued at $456,756.48. This trade represents a 8.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph Michael Taylor sold 13,095 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $23.40, for a total value of $306,423.00. Following the transaction, the director owned 48,478 shares of the company’s stock, valued at $1,134,385.20. This trade represents a 21.27% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 369,286 shares of company stock valued at $7,718,927. Company insiders own 17.70% of the company’s stock.

Hedge Funds Weigh In On CeriBell

Large investors have recently bought and sold shares of the stock. California State Teachers Retirement System lifted its stake in shares of CeriBell by 409.5% in the 2nd quarter. California State Teachers Retirement System now owns 7,352 shares of the company’s stock worth $143,000 after acquiring an additional 5,909 shares during the period. Wellington Management Group LLP lifted its position in CeriBell by 5.5% in the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares during the period. Formula Growth Ltd. acquired a new position in shares of CeriBell during the 2nd quarter valued at $603,000. Bank of America Corp DE acquired a new position in shares of CeriBell during the 2nd quarter valued at $4,619,000. Finally, PDT Partners LLC bought a new stake in shares of CeriBell in the 2nd quarter worth $1,026,000.

CeriBell Stock Down 0.4%

Shares of NASDAQ:CBLL traded down $0.09 during trading on Monday, hitting $24.11. The company’s stock had a trading volume of 13,902 shares, compared to its average volume of 344,402. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The stock’s 50-day moving average price is $19.54 and its two-hundred day moving average price is $19.22. The company has a market capitalization of $925.53 million, a PE ratio of -13.70 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. As a group, sell-side analysts expect that CeriBell will post -1.96 EPS for the current year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.